Additionally, elevated serum angiotensin converting enzyme 2 levels, associated with increased TNF-α production [45], have been observed in COVID-19 patients [2,46], suggesting that anti-TNF-α therapies used in SLE could provide benefit in treating COVID-19, as reported in some studies [7–9]. This evidence concerns the gene TNF and COVID-19.